Gastroenterology Billing Services
A 4-provider GI practice running 300 colonoscopies a month routinely creates patient billing disputes on every screening colonoscopy that converts to diagnostic — a $625 procedure that suddenly comes with patient cost-sharing because no one applied modifier PT to preserve the preventive benefit under the ACA's screening-coverage mandate. Gastroenterology billing centers on the colonoscopy code family (45378 diagnostic, 45380 with biopsy, 45385 with snare polypectomy, 45390 with EMR/endoscopic mucosal resection), the EGD set (43235 diagnostic, 43239 with biopsy, 43249 with balloon dilation), ERCP at 43260, and capsule endoscopy at 91110. The screening-to-diagnostic distinction drives both reimbursement geography and patient liability — modifier 33 (preventive service) on commercial claims and modifier PT (colorectal cancer screening test converted to diagnostic) on Medicare are not interchangeable, and getting them wrong shifts cost-sharing onto a patient who arrived expecting a $0-out-of-pocket screening. Add multi-procedure modifier 51 reductions on same-session endoscopy interventions, the split between GI-administered moderate sedation versus separately billed anesthesiologist MAC, and the buy-and-bill biologic infusion line (J1745 infliximab, J3380 vedolizumab) supporting IBD patients, and the specialty becomes a coding system where one missed modifier reshapes both revenue and the patient experience.
Who This Page Is For
Common Billing Friction in Gastroenterology
Screening-to-diagnostic colonoscopy conversion and the PT/33 modifier split
When a screening colonoscopy at CPT 45378 finds a polyp and converts to a polypectomy at 45385, two payer-specific modifier rules apply. Medicare requires modifier PT on the converted procedure to preserve the preventive cost-sharing waiver — the patient pays nothing for what started as a screen. Commercial payers under ACA preventive-services rules use modifier 33 instead. Apply the wrong modifier and the claim adjudicates as diagnostic, applying coinsurance and deductible against a procedure the patient was told would be free. Practices that confuse PT and 33 produce a steady stream of patient billing escalations that erode the front-desk schedule on top of the revenue impact.
Endoscopy multi-procedure bundling and the highest-value rule
When multiple interventions occur in the same colonoscopy or EGD — biopsy plus polypectomy at different sites, dilation plus biopsy on EGD — only the highest-value procedure pays at 100%; subsequent procedures are subject to NCCI Procedure-to-Procedure edits and the endoscopic multiple-procedure rule. The unbundle requires modifier 59 or the more specific X-modifier (XS for separate structure) plus documentation establishing distinct anatomic sites or distinct lesions. UnitedHealthcare aggressively bundles 43239 (EGD with biopsy) into 43235 (EGD diagnostic) on same-session claims and requires biopsy site documentation to release the bundle.
Anesthesia split — GI moderate sedation versus separately billed MAC
Endoscopy can be performed under GI-administered moderate sedation (typically billed by the GI as part of the procedure) or under monitored anesthesia care provided by an anesthesiologist or CRNA who bills separately under anesthesia code 00810 (lower intestine endoscopy) or 00731 (upper GI). When MAC is provided, the GI cannot bill moderate sedation. Aetna and several BCBS plans flag claims where moderate sedation appears alongside an anesthesia provider's separate claim and recoup the duplicate component. Documentation must clearly identify who provided sedation and at what level.
Biologic infusion buy-and-bill, drug waste, and step-therapy authorization
IBD treatment runs through buy-and-bill biologic infusions: J1745 (infliximab/Remicade, per 10 mg), J3380 (vedolizumab/Entyvio, per 1 mg), Q5103/Q5104/Q5121 for biosimilars, paired with infusion administration codes 96365 (initial up to 1 hour) and 96366 (each additional hour). Drug waste from single-use vials is billed with modifier JW and represents real revenue that gets dropped when not documented. Aetna and Cigna both apply step-therapy requirements before approving biologic prior authorizations — failed conventional therapy (corticosteroids, immunomodulators) must be documented with drug name, dose, duration, and clinical response before the biologic clears.
Surveillance-interval policy drift and pathology specimen coordination
USPSTF and ACG guidelines define follow-up colonoscopy intervals based on prior pathology findings (3 years for advanced adenoma, 7–10 years for normal screening), but Cigna and several BCBS plans operate proprietary surveillance schedules that deny earlier follow-ups. Pathology billing through CPT 88305 (surgical pathology, gross and microscopic, level IV) must match the specimen count documented during the procedure — three biopsied polyps must produce three pathology specimens, not two or four. Mismatches between procedure-note specimen counts and pathology billing units trigger coordinated audits that often pull six months of claims at once.
Gastroenterology-Specific Payer Issues We Watch For
Medicare
Issue: Requires modifier PT on screening colonoscopies that convert to diagnostic to waive patient cost-sharing under the preventive benefit — incorrect modifier use shifts costs to the patient
Our approach: We apply modifier PT to every screening-to-diagnostic conversion and verify the claim processes under the preventive benefit to protect patient cost-sharing rights
UnitedHealthcare
Issue: Bundles EGD biopsy (43239) with EGD diagnostic (43235) when performed in the same session, denying the biopsy as inclusive of the base procedure
Our approach: We document distinct clinical indications for each endoscopic intervention and apply modifier 59/XS when biopsies are taken from different anatomic sites than the diagnostic examination
Aetna
Issue: Requires specific prior authorization for biologic infusions with documentation of failed step therapy (conventional medications tried and failed before biologic approval)
Our approach: We compile step therapy failure documentation including drug names, dosages, duration of use, and clinical response before submitting biologic prior authorization requests
Cigna
Issue: Applies a separate polyp surveillance guideline that differs from national recommendations, denying follow-up colonoscopies scheduled earlier than their proprietary interval
Our approach: We reference Cigna's specific surveillance interval guidelines when scheduling follow-up procedures and document clinical justification when shorter intervals are medically necessary
What We Handle
Colonoscopy and EGD coding (45378, 45380, 45385, 45390, 43235, 43239, 43249)
Diagnostic, biopsy, polypectomy snare, and EMR colonoscopy coding with correct base-plus-intervention pairing. EGD with biopsy and balloon dilation under NCCI same-session rules. ERCP 43260 and capsule endoscopy 91110 included.
Screening-to-diagnostic conversion with modifier PT/33 discipline
Modifier PT applied to Medicare screening conversions; modifier 33 applied to commercial preventive services per ACA rules. Patient cost-sharing protection verified before claim release on every conversion.
Biologic infusion buy-and-bill (J1745, J3380, Q5103/Q5104) with drug waste capture
J-code unit billing, 96365/96366 infusion administration time-based add-ons, modifier JW drug waste documentation, and biosimilar Q-code substitution per payer formulary. Step-therapy documentation packaged for prior auth.
Pathology specimen coordination with 88305 unit counts
Procedure-note specimen counts reconciled to 88305 surgical pathology billing units before submission. Multi-jar specimen documentation reviewed to prevent unit-count audit findings.
ASC versus hospital outpatient site-of-service coding
POS 24 (ASC) versus POS 22 (hospital outpatient) versus POS 19 (off-campus outpatient) selection per actual location, with professional fee and facility fee coordination across the GI's contracted ASC and hospital privileges.
Sedation versus MAC anesthesia split billing
GI moderate sedation versus separately billed MAC anesthesia (00810 lower endoscopy, 00731 upper GI) coordinated to prevent duplicate-sedation recoupment. Documentation clarifies the sedation provider on every endoscopic encounter.
Key Gastroenterology CPT Codes
| CPT Code | Description | Avg. Reimbursement |
|---|---|---|
| 45378 | Diagnostic colonoscopy | $380 |
| 45385 | Colonoscopy with polypectomy by snare | $625 |
| 45380 | Colonoscopy with biopsy | $465 |
| 43239 | EGD with biopsy | $340 |
| 43249 | EGD with balloon dilation | $520 |
| 43260 | ERCP with diagnostic evaluation | $890 |
| 91065 | Hydrogen breath test | $85 |
| J1745 | Infliximab (Remicade) injection, 10 mg | $115/unit |
Real Results
The Challenge
A 4-provider GI practice performing 300+ colonoscopies per month was losing revenue on screening-to-diagnostic conversions, multi-procedure endoscopy unbundling, and had $22K monthly in biologic infusion billing errors
Our Approach
We implemented automated screening-to-diagnostic conversion coding with PT modifier tracking, corrected endoscopy bundling using CCI-compliant modifier application, and restructured biologic buy-and-bill workflows
Key Outcomes
- check_circle Colonoscopy revenue per procedure increased by $165
- check_circle Endoscopy multi-procedure revenue increased 22%
- check_circle Biologic infusion billing errors eliminated — recovered $48K in 90 days
- check_circle Patient complaints about unexpected colonoscopy charges dropped to zero
“We were creating patient billing problems on every converted screening colonoscopy. MedPrecision fixed the modifier issue and our patients stopped getting surprised with bills.”
Why General Billing Teams Miss Gastroenterology Issues
General billing staff handle dozens of specialties and rarely develop the depth needed for gastroenterology coding nuances. Here is what gets missed.
Modifier and bundling errors
Specialty-specific modifier rules and CCI edits are frequently overlooked by teams that do not work exclusively in gastroenterology.
Under-coding high-complexity visits
Gastroenterology encounters often qualify for higher-level E/M codes, but generalist billers default to mid-level codes to avoid audit risk.
Missed payer-specific rules
Each payer has unique coverage and documentation requirements for gastroenterology procedures that general teams rarely memorize.
Slow denial turnaround
Without specialty knowledge, appeal letters lack the clinical specificity needed to overturn gastroenterology denials quickly.
“The screening-to-diagnostic colonoscopy conversion is where most GI practices create both revenue and compliance problems. One wrong modifier choice costs you the procedure payment and creates a patient billing dispute.”
MedPrecision Billing Team
GI Procedure Coding Specialist
Transition Plan
Switching billing partners should not disrupt patient care or cash flow. Our transition plan is designed for zero downtime.
Discovery and Specialty Audit
We review your current gastroenterology billing workflows, denial patterns, and payer mix to build a tailored onboarding plan.
System Integration
We connect to your EHR and practice management system, configure specialty-specific code sets, and validate charge capture workflows.
Parallel Billing Period
We run billing in parallel with your current process for 2-4 weeks to verify accuracy before taking over completely.
Full Transition and Reporting
Once validated, we assume full billing responsibility with monthly reporting dashboards and a dedicated account manager.
Gastroenterology Billing Terms
- Screening-to-Diagnostic Conversion
- When a colonoscopy initiated as a preventive screening procedure converts to a diagnostic procedure due to findings such as polyps or lesions. Requires modifier PT to preserve the patient's preventive benefit and waive cost-sharing.
- CCI Bundling Edits
- Correct Coding Initiative edits that define which GI procedure codes cannot be billed together. Endoscopy bundling rules are among the most complex in medical billing, particularly for same-session interventions.
- Buy-and-Bill
- A billing model where the practice purchases biologic medications (Remicade, Entyvio), administers them to patients, and bills the payer for both the drug cost (J-code) and the infusion administration. Requires careful drug waste documentation and inventory management.
- Modifier PT
- Colorectal cancer screening test converted to diagnostic — a modifier applied to colonoscopy claims when a screening procedure results in polyp removal or biopsy. Ensures the patient retains their preventive benefit cost-sharing protections.
- Endoscopy Base Code
- The primary procedure code for an endoscopic examination (45378 for colonoscopy, 43235 for EGD) to which intervention add-on codes are appended. Only the highest-value intervention is typically billable separately from the base code without modifiers.
- Drug Waste Documentation
- Required documentation of unused biologic medication from single-use vials. Medicare and most commercial payers reimburse for documented drug waste using modifier JW, which can represent significant revenue for infusion practices.
Last updated: 2026-04-18
Common Questions
Common questions about gastroenterology billing services.
Request a Specialty Billing Review
See how specialty-specific billing support can improve reimbursement visibility for gastroenterology billing services.
Request Review arrow_forwardHow do you handle billing when a screening colonoscopy finds and removes polyps?
We code the procedure as a colonoscopy with polypectomy using the appropriate technique-specific code (snare, hot biopsy, etc.) and apply modifier PT to indicate it began as a screening procedure. This preserves the patient's preventive screening benefit while capturing the interventional component.
Can you bill for multiple endoscopic procedures in the same session?
Yes, when properly documented and coded. We apply modifier 59 or XS to distinguish separate procedures and follow CCI bundling edits to ensure each intervention is billable. For example, a colonoscopy with both polypectomy and biopsy at different sites can be billed separately.
How do you manage biologic infusion billing for GI practices?
We handle the complete buy-and-bill cycle including drug J-code billing (J1745 for Remicade, J3380 for Entyvio), infusion administration codes with time-based add-ons, drug waste documentation, and prior authorization for continued therapy.
Related Services
Related Specialties
Related Resources
Available In
Request a Specialty Billing Review
Find out if your endoscopy and colonoscopy coding is missing revenue on modifier and pathology add-ons.